Medicine details
Image | |
Name | Pitavas |
Dosage | Tablet |
Generic Name | Pitavastatin |
Classes |
Metabolic Agent Antihyperlipidemic/Lipid Lowering Agent Statin |
Diseases |
Dietary Problem High Cholesterol |
Company | Aristopharma Limited |
Drug Package Details
Strength | 2 mg |
Storage Condition | |
Origin Country | Bangladesh |
Commercial Pack | 30 |
Price per pack | ৳ 298.98 |
Cost per pack | ৳ 263.10 |
Package unit | 10 tabs strip |
Price per unit | ৳ 9.97 |
Cost per unit | ৳ 8.77 |
Discount | 0 |
Coupon | |
Remarks |
Pitavastatin
Pitavastatin is a lipid lowering medication that acts by inhibiting the enzyme HMG Co-A reductase. HMG Co-A reductase is an enzyme essential for the synthesis of cholesterols.
Pitavastatin is indicated for the following cases-
- Hyperlipidemia
- Prevention of Cardiovascular diseases (myocardial infarction, stroke, angina etc.)
- Coronary heart diseases
- PITAVASTATIN is available as Tablets of- 1 mg, 2 mg, and 4 mg.
- PITAVASTATIN is taken orally once daily with or without food at the same time each day.
- The dose of PITAVASTATIN should be individualized according to patient characteristics, goal of therapy, and response.
- After initiation or upon titration, analyze lipid levels after 4 weeks and adjust the dosage accordingly.
- The recommended starting PITAVASTATIN dosage is 2 mg once daily.
- The maximum recommended dosage is PITAVASTATIN 4 mg once daily
- The recommended starting dosage for patients with moderate and severe renal impairment (estimated glomerular
- filtration rate 30-59 and 15-29 mL/min/1.73 m2, respectively) as well as end-stage renal disease on hemodialysis is PITAVASTATIN 1 mg once daily and the maximum dose is 2 mg once daily
- Patients taking erythromycin, should not exceed 1 mg once daily while patients taking rifampin, should not exceed 2 mg once daily
Side effects associated with the use of PITAVASTATIN include-
- Hepatic dysfunction
- myalgia
- muscle spasm
- headache
- dizziness
- influenza
- nasopharyngitis
- insomnia
- PITAVASTATIN may cause myopathy (muscle pain, tenderness, or weakness with creatine kinase (CK) above ten times the upper limit of normal) and rhabdomyolysis (with or without acute renal failure secondary to myoglobinuria). Rare fatalities have occurred as a result of rhabdomyolysis with statin use, including PITAVASTATIN.
- There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment
- Increases in serum transaminases have been reported with PITAVASTATIN. In most cases, the elevations were transient and either resolved or improved on continued therapy or after a brief interruption in therapy. There have been rare post-marketing reports of fatal and non-fatal hepatic failure in patients taking statins, including PITAVASTATIN.
- Increases in HbA1c and fasting serum glucose levels have been reported with statins, including PITAVASTATIN.
Contraindication
PITAVASTATIN is contraindicated in patients hypersensitive to the medicine itself or other statins, such as-
PITAVASTATIN contraindicated with the concomitant use of-
PITAVASTATIN is contraindicated in the following health conditions-
- Liver problems
- Pregnancy
- Lactation